Nivolumab (NIVO) + low-dose ipilimumab (IPI) as first-line (1L) therapy in microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Two-year clinical update.

Authors

Heinz-Josef LenzFollow
Sara LonardiFollow
Vittorina ZagonelFollow
Eric Van CutsemFollow
M Luisa LimonFollow
Ka Yeung Mark WongFollow
Alain HendliszFollow
Massimo AgliettaFollow
Pilar Garcia-AlfonsoFollow
Bart NeynsFollow
Fabio Gelsomino
Dana Backlund CardinFollow
Tomislav DragovitchFollow
Usman Shah MD, Lehigh Valley Health NetworkFollow
Jing Yang
Jean-Marie LedeineFollow
Michael J. OvermanFollow

Publication/Presentation Date

5-2020

Published In/Presented At

Lenz, H., Lonardi, S., Zagonel, V., Van Cutsem, E., Limon, L., Wong, K., Hendlisz, A., Aglietta, M., Garcia-Alfonso, P., Neyns, B., Gelsomino, F., Backlund Cardin, D., Dragovich, T., Shah, U., Yang, J., Ledeine, J., & Overman, M. (2020, May). Nivolumab (NIVO) + low-dose ipilimumab (IPI) as first-line (1L) therapy in microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Two-year clinical update. Presentation presented at ASCO 2020 Annual Meeting, Virtual.

Disciplines

Medicine and Health Sciences | Oncology

Department(s)

Department of Medicine, Hematology-Medical Oncology Division, Department of Medicine Faculty

Document Type

Presentation